The protein encoded by this gene is a member of the TNF-receptor superfamily. This receptor is expressed preferentially by activated and antigen-experienced T lymphocytes. TNFRSF25 is also highly expressed by FoxP3 positive regulatory T lymphocytes. TNFRSF25 is activated by a monogamous ligand, known as TL1A (TNFSF15), which is rapidly upregulated in antigen presenting cells and some endothelial cells following Toll-Like Receptor or Fc receptor activation. This receptor has been shown to signal both through the TRADD adaptor molecule to stimulate NF-kappa B activity or through the FADD adaptor molecule to stimulate caspase activation and regulate cell apoptosis.[2]
Multiple alternatively spliced transcript variants of this gene encoding distinct isoforms have been reported, most of which are potentially secreted molecules. The alternative splicing of this gene in B and T cells encounters a programmed change upon T-cell activation, which predominantly produces full-length, membrane bound isoforms, and is thought to be involved in controlling lymphocyte proliferation induced by T-cell activation. Specifically, activation of TNFRSF25 is dependent upon previous engagement of the T cell receptor. Following binding to TL1A, TNFRSF25 signaling increases the sensitivity of T cells to endogenous IL-2 via the IL-2 receptor and enhances T cell proliferation. Because the activation of the receptor is T cell receptor dependent, the activity of TNFRSF25 in vivo is specific to those T cells that are encountering cognate antigen. At rest, and for individuals without underlying autoimmunity, the majority of T cells that regularly encounter cognate antigen are FoxP3+ regulatory T cells. Stimulation of TNFRSF25, in the absence of any other exogenous signals, stimulates profound and highly specific proliferation of FoxP3+ regulatory T cells from their 8-10% of all CD4+ T cells to 35-40% of all CD4+ T cells within 5 days.[5]
Therapeutics
Therapeutic agonists of TNFRSF25 can be used to stimulate Treg expansion, which can reduce inflammation in experimental models of asthma, allogeneic solid organ transplantation and ocular keratitis.[5][6][7] Similarly, because TNFRSF25 activation is antigen dependent, costimulation of TNFRSF25 together with an autoantigen or with a vaccine antigen can lead to exacerbation of immunopathology or enhanced vaccine-stimulated immunity, respectively.[8] TNFRSF25 stimulation is therefore highly specific to T cell mediated immunity, which can be used to enhance or dampen inflammation depending on the temporal context and quality of foreign vs self antigen availability. Stimulation of TNFRSF25 in humans may lead to similar, but more controllable, effects as costimulatory blockade targeting molecules such as CTLA-4 and PD-1.[3]
References
↑Bodmer JL, Burns K, Schneider P, Hofmann K, Steiner V, Thome M, Bornand T, Hahne M, Schröter M, Becker K, Wilson A, French LE, Browning JL, MacDonald HR, Tschopp J (Jan 1997). "TRAMP, a novel apoptosis-mediating receptor with sequence homology to tumor necrosis factor receptor 1 and Fas(Apo-1/CD95)". Immunity. 6 (1): 79–88. doi:10.1016/S1074-7613(00)80244-7. PMID9052839.
↑ 2.02.1Kitson J, Raven T, Jiang YP, Goeddel DV, Giles KM, Pun KT, Grinham CJ, Brown R, Farrow SN (Nov 1996). "A death-domain-containing receptor that mediates apoptosis". Nature. 384 (6607): 372–5. doi:10.1038/384372a0. PMID8934525.
Metheny-Barlow LJ, Li LY (2006). "Vascular endothelial growth inhibitor (VEGI), an endogenous negative regulator of angiogenesis". Seminars in Ophthalmology. 21 (1): 49–58. doi:10.1080/08820530500511446. PMID16517446.
Chinnaiyan AM, O'Rourke K, Yu GL, Lyons RH, Garg M, Duan DR, Xing L, Gentz R, Ni J, Dixit VM (Nov 1996). "Signal transduction by DR3, a death domain-containing receptor related to TNFR-1 and CD95". Science. 274 (5289): 990–2. doi:10.1126/science.274.5289.990. PMID8875942.
Bonaldo MF, Lennon G, Soares MB (Sep 1996). "Normalization and subtraction: two approaches to facilitate gene discovery". Genome Research. 6 (9): 791–806. doi:10.1101/gr.6.9.791. PMID8889548.
Marsters SA, Sheridan JP, Donahue CJ, Pitti RM, Gray CL, Goddard AD, Bauer KD, Ashkenazi A (Dec 1996). "Apo-3, a new member of the tumor necrosis factor receptor family, contains a death domain and activates apoptosis and NF-kappa B". Current Biology. 6 (12): 1669–76. doi:10.1016/S0960-9822(02)70791-4. PMID8994832.
Warzocha K, Ribeiro P, Charlot C, Renard N, Coiffier B, Salles G (Jan 1998). "A new death receptor 3 isoform: expression in human lymphoid cell lines and non-Hodgkin's lymphomas". Biochemical and Biophysical Research Communications. 242 (2): 376–9. doi:10.1006/bbrc.1997.7948. PMID9446802.
Grenet J, Valentine V, Kitson J, Li H, Farrow SN, Kidd VJ (May 1998). "Duplication of the DR3 gene on human chromosome 1p36 and its deletion in human neuroblastoma". Genomics. 49 (3): 385–93. doi:10.1006/geno.1998.5300. PMID9615223.
Jiang Y, Woronicz JD, Liu W, Goeddel DV (Jan 1999). "Prevention of constitutive TNF receptor 1 signaling by silencer of death domains". Science. 283 (5401): 543–6. doi:10.1126/science.283.5401.543. PMID9915703.
Kaptein A, Jansen M, Dilaver G, Kitson J, Dash L, Wang E, Owen MJ, Bodmer JL, Tschopp J, Farrow SN (Nov 2000). "Studies on the interaction between TWEAK and the death receptor WSL-1/TRAMP (DR3)". FEBS Letters. 485 (2–3): 135–41. doi:10.1016/S0014-5793(00)02219-5. PMID11094155.
Frankel SK, Van Linden AA, Riches DW (Oct 2001). "Heterogeneity in the phosphorylation of human death receptors by p42(mapk/erk2)". Biochemical and Biophysical Research Communications. 288 (2): 313–20. doi:10.1006/bbrc.2001.5761. PMID11606045.
Migone TS, Zhang J, Luo X, Zhuang L, Chen C, Hu B, Hong JS, Perry JW, Chen SF, Zhou JX, Cho YH, Ullrich S, Kanakaraj P, Carrell J, Boyd E, Olsen HS, Hu G, Pukac L, Liu D, Ni J, Kim S, Gentz R, Feng P, Moore PA, Ruben SM, Wei P (Mar 2002). "TL1A is a TNF-like ligand for DR3 and TR6/DcR3 and functions as a T cell costimulator". Immunity. 16 (3): 479–92. doi:10.1016/S1074-7613(02)00283-2. PMID11911831.
Wen L, Zhuang L, Luo X, Wei P (Oct 2003). "TL1A-induced NF-kappaB activation and c-IAP2 production prevent DR3-mediated apoptosis in TF-1 cells". The Journal of Biological Chemistry. 278 (40): 39251–8. doi:10.1074/jbc.M305833200. PMID12882979.
Osawa K, Takami N, Shiozawa K, Hashiramoto A, Shiozawa S (Sep 2004). "Death receptor 3 (DR3) gene duplication in a chromosome region 1p36.3: gene duplication is more prevalent in rheumatoid arthritis". Genes and Immunity. 5 (6): 439–43. doi:10.1038/sj.gene.6364097. PMID15241467.